Ramaphosa's energy plan Webinar banner

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

SA scientists analyse eight samples from coronavirus pa...

Maverick Citizen

COVID-19

SA scientists analyse eight samples from coronavirus patients showing ‘novel mutations’

(Photo: iStock)

The National Institute for Communicable Diseases has confirmed it is analysing eight samples taken from patients who tested positive for coronavirus infections. The samples have been flagged for having ‘novel mutations’.

Eight samples from South African patients, containing SARS-CoV-2 viruses that have novel mutations, are currently being studied by the country’s genomic sequencing teams looking for new mutations or subvariants.  

Professor Anna von Gottberg said they are analysing these eight sequences with other sequences globally, as well as monitoring whether similar sequences are detected in new specimens submitted to South Africa’s team of scientists looking for possible mutations of the virus. 

“For now, these sequences are not from very recent specimens and the numbers are very small, so it is difficult to predict what will happen going forward,” Von Gottberg said. 

The eight samples with novel mutations of the virus were first identified in the latest Genomic Surveillance Report, which was based on samples collected up to 22 July.  

According to this report, the subvariants of Omicron are still most prevalent in samples from infected patients and were identified in 98% of the genomes analysed. 

The Omicron lineages BA.4 and BA.5 increased in prevalence in March (16%) and together were dominant in April (73%), May (93%) and June (91%). 

Another subvariant, BA.2.12.1, currently dominant in the US, among other countries, was detected in South Africa at a low prevalence in May and June. 

According to the latest situational report from the World Health Organization (WHO), 6.6 million new cases of the disease were reported last week with 12,600 deaths. 

Japan had a high number of new cases: 969,068 with a 73% weekly increase. The US had 860,097 new cases, Germany had 565,518, Italy had 531,327 and France had 508,620. However, case numbers in all these countries were declining. 

South Africa had a low number of cases, with the National Institute for Communicable Diseases reporting 381 new cases on Wednesday and another five deaths.  

Apart from the Omicron sublineages BA1, BA2, BA4 and BA5, the WHO has indicated that it is also monitoring BA.2.12.1, a sister lineage of BA2; BA2.9.1, a BA2 sublineage; BA2.11, a BA2 sublineage; BA2.13; and BA2.75. 

The lineages are differentiated mostly in mutations on the virus’ spike protein. According to the WHO, these different viruses are classified as subvariants of Omicron until sufficient evidence arises that the virus characteristics are substantially different from what is known about the Omicron variant. DM/MC

Gallery

"Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]"

Please peer review 3 community comments before your comment can be posted